ViroPharma (NASDAQ:VPHM) Building Foundation on Cinryze

ViroPharma (NASDAQ:VPHM) has expanded its meager offerings to a potential blockbuster with Cinryze, which it competes alone with, as it's the only FDA-approved C1 esterase inhibitor therapy for attacks from hereditary angioedema.

Capstone said, "The company has successfully completed the transition from a high risk one product (Vancocin, without patent protection) company to a company with a well protected asset, Cinryze that address an important medical need...Cinryze was among the best ever launches of an orphan drug. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy for routine prevention of hereditary angioedema (HAE) attacks...Two near term catalysts may further reduce the risk in valuation. 1). EMEA approval of Cinryze 2). FDA approval of new manufacturing capacity."

Capstone Investments initiated coverage on ViroPharma with a "Buy" rating. They closed Wednesday at $17.93, down $0.04, or 0.21 percent. Capstone has a price target on them of $21.